As of June 10, 2025, Ayala Pharmaceuticals Inc (ADXS) reports a Current Ratio of 0.30.
Current Ratio assesses a company's ability to pay short-term debts by comparing liquid assets to liabilities, with higher ratios signaling better financial health.
Historical Trend of Ayala Pharmaceuticals Inc's Current Ratio
Over recent years, Ayala Pharmaceuticals Inc's Current Ratio has shown significant volatility. The table below summarizes the historical values:
| Date | Current Ratio |
|---|---|
| 2023-12-31 | 0.30 |
| 2022-10-31 | 11.22 |
| 2021-10-31 | 5.48 |
| 2020-10-31 | 8.45 |
| 2019-10-31 | 8.02 |
This slight downward trend highlights how Ayala Pharmaceuticals Inc manages its short-term assets and liabilities over time.
Comparing Ayala Pharmaceuticals Inc's Current Ratio to Peers
To better understand Ayala Pharmaceuticals Inc's position, it's useful to compare its Current Ratio against industry peers. Below are selected comparisons:
| Company | Current Ratio |
|---|---|
| Ayala Pharmaceuticals Inc (ADXS) | 0.30 |
| Aikido Pharma Inc (AIKI) | 85.66 |
| Merrimack Pharmaceuticals Inc (MACK) | 43.50 |
| Synthetic Biologics Inc (SYN) | 19.37 |
| CohBar Inc (CWBR) | 15.75 |
| Soleno Therapeutics Inc (SLNO) | 15.47 |
Compared to its competitors, Ayala Pharmaceuticals Inc's Current Ratio is among the lowest compared to peers, suggesting tighter liquidity management or potential short-term obligations concerns.